Effects of celiprolol and simvastatin on the calculated risk of coronary heart disease (the Celisimva study)

References

• Martin MJ, Hulley SB, Browner WS, Kuller LH, Wentworth D. Serum cholesterol, blood pressure and mortality: implications from a cohort of 361 662 men. Lancet. 1986; ii: 933–6
   Google Scholar
• Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other societies on Coronary Prevention. Eur Heart J. 1998; 19: 1434–1503
   PubMed Web of Science ®Google Scholar
• Anderson KM, Wilson PW, Odell PM, Kannel WBl. Un updated coronary risk profile. A statement for health professionals. Circulation. 1991; 83: 356–62
   PubMed Web of Science ®Google Scholar
• Assman G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002; 105: 310–5
   PubMed Web of Science ®Google Scholar
• Empana, JP, Ducimetiere, P, Arveiler, D, Ferrieres, J, Evans, A, Ruidavets, JB, , on behalf of the PRIME study group, et al. Are the Framingham and Procam coronary heart disease risk functions applicable to different European populations?. Eur Heart J. 2003;24:1903–11.
   PubMed Web of Science ®Google Scholar
• Hense HW, Schulte H, Lowel H, Assmann G, Keil U. Framingham risk function overestimates risk of coronary heart disease in men and women from Germany- results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J. 2003; 24: 937–45
   PubMed Web of Science ®Google Scholar
• Brindle P, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, Ebrahim S. Predictive accuracy of the Framingham coronary risk score in British men: prospective cohort study. BMJ. 2003; 327: 1267
   PubMed Web of Science ®Google Scholar
• The West of Scotland Coronary Prevention Study Group. Baseline risk factors and their association with outcome in the West of Scotland Coronary Prevention Study. Am J Cardiol. 1997; 79: 759–62
   Google Scholar
• Hense HW. Risk factor scoring for coronary heart disease. BMJ. 2003; 327: 1238–9
   PubMed Web of Science ®Google Scholar
• Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA. 1982; 248: 1465–77
   PubMed Web of Science ®Google Scholar
• Strandberg TE, Salomaa VV, Naukkarinen VA, Vanhanen HT, Sarna SJ, Miettinen TA. Long-term mortality after 5-year multifactorial primary prevention of carfdiovascular disease in middle-aged men. JAMA. 1991; 266: 1225–9
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlöf, Poulter NR, Wedel H, Beevers G, Caulfield M, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003; 361: 1149–58
   PubMed Web of Science ®Google Scholar
• Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. N Engl J Med. 1995; 333: 1301–7
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals:a randomised placebo-controlled trial. Lancet. 2002; 360: 7–22
   PubMed Web of Science ®Google Scholar
• ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomised to pravastatin vs usual care: the Antihypertensive and Lipid-Lowerng Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA. 2002; 288: 2998–3007
   PubMed Web of Science ®Google Scholar
• Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al. Health outcomes associated with antihypertensive therapies used as first-line agents: a systematic review andf meta-analysis. JAMA. 1997; 277: 739–45
   PubMed Web of Science ®Google Scholar
• Neaton JD, Grimm RH, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, et al. Treatment of mild hypertension study. Final results. JAMA. 1993; 270: 713–24
   PubMed Web of Science ®Google Scholar
• Milne RJ, et Buckely MMT. Celiprolol. an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in cardiovascular disease. Drugs. 1991; 41: 941–969
   PubMed Web of Science ®Google Scholar
• Plosker GL, Simvastatin McTavish P. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolemia. Drugs. 1995; 50: 334–63
   PubMed Web of Science ®Google Scholar
• Kattainen A, Reunanen A, Koskinen S, Martelin T, Knekt P, Aromaa A. Secular changes in prevalence of crdiovascular diseases in elderly Finns. Scand J Public Health. 2002; 30: 274–80
   PubMed Web of Science ®Google Scholar
• Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation. 2000; 18: 207–13
   Google Scholar
• Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial – Blood Pressure Loweruing Arm (ASCOT-BPLA): a multicentre randomised trial. Lancet. 2005; 366: 895–906
   PubMed Web of Science ®Google Scholar
• HeartScore Web Application (2005) Available from:, , URL:https://www.escardio.org/knowledge/ decision_tools/heartscore/eu_high/Score + Cumputing/
   Google Scholar
• The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in higg-risk patients. N Engl J Med. 2000; 342: 145–153
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002; 359: 995–1003
   PubMed Web of Science ®Google Scholar